• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: NOVO NORDISK A/S, MEDICAL SYSTEMS NOVOPEN 4 INSULIN DELIVERY DEVICE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

NOVO NORDISK A/S, MEDICAL SYSTEMS NOVOPEN 4 INSULIN DELIVERY DEVICE Back to Search Results
Model Number N/A
Device Problem Insufficient Information (3190)
Patient Problem No Code Available (3191)
Event Date 01/01/2019
Event Type  malfunction  
Event Description
Acetonuria ketonuria, novopen 4 spoiled mixtard 30 penfills device malfunction, novopen 4 spoiled mixtard 30 penfills by formation of aggregates, drug-device interaction. Formation of aggregates different from the normal turbidity of the mixtard 30 liquid product physical issue. Case description: this serious spontaneous case from (b)(6) was reported by a consumer as "acetonuria(acetonuria)" beginning on an unspecified date of 2019, "novopen 4 spoiled mixtard 30 penfills(device malfunction)" beginning on an unspecified date of 2019, "novopen 4 spoiled mixtard 30 penfills by formation of aggregates(drug-device interaction)" beginning on an unspecified date of 2019, "formation of aggregates different from the normal turbidity of the mixtard 30(liquid product physical issue)" beginning on an unspecified date of 2019, and concerned a (b)(6) year-old female patient who was treated with novopen 4 (insulin delivery device) from unknown start date for "type 1 diabetes mellitus", mixtard 30 hm penfill (insulin human) from unknown start date and ongoing for "type 1 diabetes mellitus" (dose and frequency 20 iu, bid (morning and night) ), and actrapid penfill (insulin human) from unknown start date and ongoing for "type 1 diabetes mellitus" (dose and frequency 10 iu, tid (with each meal) ). Patient's height: 165 cm. Patient's weight (was reported in range 63-65 kg) and body mass index (bmi) was not reported. Current condition: type 1 diabetes mellitus (since 21 years ago) , hypertension (since 4 months ago). It was reported that novopen 4 spoiled patient's mixtard 30 penfills by formation of aggregates different from the normal turbidity of the mixtard 30 during (b)(6) 2019 which caused the patient to be hospitalized for 4 days due to acetonuria and during hospitalization, patient stopped injecting insulin with the novopen 4. The patient could not confirm the blood glucose level at that event. The patient's causality is probable regarding to the novopen 4 used with the mixtard 30 penfills with batch number (gvgh078) while unlikely regarding the other pen & insulins. Batch numbers: novopen 4: gvgh078, mixtard 30 hm penfill: asku, actrapid penfill: asku. Action taken to novopen 4 was product discontinued due to adverse event (ae). Action taken to mixtard 30 hm penfill was not reported. Action taken to actrapid penfill was not reported. The outcome for the event "acetonuria(acetonuria)" was recovered. The outcome for the event "novopen 4 spoiled mixtard 30 penfills(device malfunction)" was not reported. The outcome for the event "novopen 4 spoiled mixtard 30 penfills by formation of aggregates(drug-device interaction)" was not reported. The outcome for the event "formation of aggregates different from the normal turbidity of the mixtard 30(liquid product physical issue)" was not reported. Investigation results: product name: actrapid® penfill® 3 ml 100iu/ml, batch: unknown, no investigation was possible, because neither sample nor batch number was available. Product name: mixtard® 30 penfill® 3 ml 100iu/ml, batch: unknown, no investigation was possible, because neither sample nor batch number was available. Product name: novopen® 4, batch: gvgh078, the product was not returned for examination. No investigation was possible, because neither sample nor batch number was available. Manufacturer final comment: on 24-jul-2020: the suspected device (novopen 4) has not been returned to novo nordisk for evaluation. The reference sample was found to be normal. Batch documentation has been reviewed and found to be normal. With limited information regarding the handling of suspected device, it is not possible to identify a clear root-cause of the experienced adverse event. Patient's underlying medical condition of type 1 diabetes mellitus is a significant factor for the development of acetonuria. Company comment: ketonuria and drug - device interaction are assessed as unlisted, liquid product physical issue is assessed as listed according to the nov nordisk current ccds in mixtard 30 hm penfill. The reported events are assessed as unlisted for actrapid penfill as the events occurred with mixtard 30 hm penfill. The suspected device (novopen 4) has not been returned to novo nordisk for evaluation. The reference sample was found to be normal. Batch documentation has been reviewed and found to be normal. With limited information regarding the handling of suspected device, it is not possible to identify a clear root-cause of the experienced adverse event. Patient's underlying medical condition of type 1 diabetes mellitus is a significant factor for the development of acetonuria. This single case report is not considered to change the current knowledge of the safety profile of mixtard 30 hm penfill and actrapid penfill. Reporter comment: -her weight (b)(6) kg. Evaluation summary: investigation results, product name: novopen® 4, batch: gvgh078, the product was not returned for examination. No investigation was possible, because neither sample nor batch number was available.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand NameNOVOPEN 4
Type of DeviceINSULIN DELIVERY DEVICE
Manufacturer (Section D)
NOVO NORDISK A/S, MEDICAL SYSTEMS
hilleroed,
DA
Manufacturer (Section G)
NOVO NORDISK A/S, MEDICAL SYSTEMS
brennum park
hilleroed, 3400,
DA
Manufacturer Contact
p.o. box 846
plainsboro, NJ 08536
8007276500
MDR Report Key10363672
MDR Text Key256740527
Report Number9681821-2020-00034
Device Sequence Number1
Product Code FMF
Combination Product (y/n)Y
PMA/PMN Number
20-986
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type consumer,foreign
Type of Report Initial
Report Date 07/06/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received08/04/2020
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Device Operator Other
Device Model NumberN/A
Device Catalogue Number185490
Device Lot NumberGVGH078
Was Device Available for Evaluation? No
Was the Report Sent to FDA?
Event Location No Information
Date Manufacturer Received07/06/2020
Is This a Reprocessed and Reused Single-Use Device? No

Patient Treatment Data
Date Received: 08/04/2020 Patient Sequence Number: 1
-
-